A randomized phase 2 study of bicalutamide with or without metformin for biochemical recurrence in overweight or obese prostate cancer patients (BIMET-1)
Marijo Bilušić, Nicole J. Toney, Renee N. Donahue, Susan Wróblewski, Matthew R. Zibelman, Pooja Ghatalia, Eric A. Ross, Fatima Karzai, Ravi A. Madan, William L. Dahut, James L. Gulley, Jeffrey Schlom, Elizabeth R. Plimack, Daniel M. Geynisman
Topics & Concepts
MedicineBicalutamideMetforminProstate cancerInternal medicineClinical endpointUrologyRandomized controlled trialOncologyCancerGastroenterologyInsulinAndrogen receptorMetabolism, Diabetes, and CancerCancer Risks and FactorsDiabetes Treatment and Management